Nanocopoeia

What Nanocopoeia does

Nanocopoeia, LLC is a privately held specialty research company founded in 2001 in the Twin Cities, Minnesota area, through a technology license with the University of Minnesota. Originally operating as a business-to-business technology services provider focused on medical devices and advanced nano-scale coatings, the company reorganized around 2021 to pivot toward generating macro-particles for oral-solid drug development. It targets pharmaceutical partners facing high-value, high-barrier insolubility, bioavailability, and related drug-product challenges, with particular emphasis on 505(b)(2) development opportunities.

The company's core product is its proprietary ElectronanoSpray (ENS) atomization platform, developed from the Taylor Cone hydrodynamic principle operating in Cone-jet mode. The high-voltage unipolar atomization process produces homogeneous, macro-scale drug-formulation particles with high surface area and uniformity, using common pharmaceutical-grade excipients and solvents that are removed to residual levels well below ICH requirements. The ENS platform is positioned as a tool to overcome challenging insolubility issues, increase bioavailability, reduce defects, and improve patient safety, convenience, compliance, and drug effectiveness.

Nanocopoeia monetizes through a B2B technology services model and co-development/out-licensing arrangements with pharmaceutical partners. Revenue streams are described as professional services for nano-scale coating and formulation work, paired with licensing and royalty arrangements tied to co-developed drug products. The company has a small team of 11-50 employees, backed by what it describes as substantial but undisclosed investor capital, and operates from its headquarters at 639 Campus Drive, New Brighton, MN.

Name

Nanocopoeia

Legal name

Nanocopoeia, LLC

Website

https://nanocopoeia.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanocopoeia is a privately held specialty research company that uses its proprietary ElectronanoSpray (ENS) atomization technology to solve drug insolubility and bioavailability challenges, partnering with pharmaceutical companies on co-development and out-licensing of 505(b)(2) oral-solid drug opportunities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Formulation Services

NAICS

Research and Development in Nanotechnology (541713), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

akta.pro secondary industries

Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical formulation services
• Drug solubility solutions
• Bioavailability enhancement
• Nanoparticle drug development
• 505(b)(2) drug development

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Technology Services: Business-to-business technology services model providing nano-scale coating processes and drug formulation capabilities to pharmaceutical partners.
2. Co-development and Licensing: Co-development partnerships and out-licensing of drug formulations for oral-solid drug development, particularly 505(b)(2) opportunities.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Nanocopoeia provides pharmaceutical drug formulation services using its proprietary ElectronanoSpray (ENS) atomization technology, which creates homogeneous, macro-scale drug particles that overcome challenging insolubility issues and improve bioavailability performance. The company operates a B2B technology services and co-development model, partnering with pharmaceutical companies on oral-solid drug development, including 505(b)(2) opportunities, and out-licensing its formulations.

Product overview

Nanocopoeia is a specialty research company offering a unified technology platform centered on its proprietary ElectronanoSpray (ENS) atomization technology. The company operates a business-to-business technology services model, providing pharmaceutical companies with access to its ENS platform for drug formulation development. ENS enables the creation of macro-scale drug particles that overcome insolubility challenges and improve bioavailability performance, supporting 505(b)(2) drug development opportunities.

Differentiator

Problem solved

Functional benefit

Products and services

• ElectronanoSpray (ENS) Technology Platform Proprietary atomization technology based on the Taylor Cone hydrodynamic principle operating in Cone-jet mode. Produces homogeneous, macro-scale drug formulation particles with high surface area and uniformity, addressing insolubility and bioavailability challenges in pharmaceutical development for 505(b)(2) opportunities.
• Pharmaceutical Co-development and Out-licensing Services B2B engagement offering pharmaceutical partners co-development and out-licensing arrangements using the ENS platform, focused on building long-term value on oral-solid drug products targeting 505(b)(2) development pathways.

Quantifiable outcome

• Residual solvents (RS) proving to be well below ICH requirements

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• University of MinnesotacoreStrategic or Co-development Partner · 1 January 2001Technology licensing partnership established in 2001 through which Nanocopoeia was founded. Initial technology focused on medical devices and advanced nano-scale coating processes.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Bend Research (part of Lonza): A bioavailability and solubility-focused formulation CRO/CDMO, now part of Lonza, specializing in spray-dried dispersions and particle engineering for poorly soluble drugs — directly comparable to Nanocopoeia's ENS platform and 505(b)(2) partner model.
• Hovione: CDMO with strong particle engineering, spray drying, and bioavailability-enhancement capabilities, serving pharmaceutical partners with similar formulation services and tech-platform partnering models.
• Solvias: CRO/CDMO with deep solid-state chemistry, preformulation, and particle engineering expertise, serving pharma clients on solubility and bioavailability challenges — closely comparable to Nanocopoeia's technical focus.
• Crystal Pharmatech: Specialty CRO focused on solid-form selection, crystallization, and preformulation services for poorly soluble drugs — closely aligned with Nanocopoeia's solubility/bioavailability value proposition.

Broad incumbents

• Catalent: Large global CDMO offering broad formulation, bioavailability, and drug product development services including OptiForm® and similar solubility-enhancement platforms — overlaps Nanocopoeia's scope at much greater scale.
• Patheon (Thermo Fisher Scientific): Major global CDMO providing drug substance and drug product development including formulation services for poorly soluble compounds — broad incumbent with overlapping capabilities.
• Lonza: Global CDMO leader offering bioavailability and formulation services including the Bend Research platform — a broad incumbent whose overlapping capabilities directly compete with Nanocopoeia.

Emerging players

• Vectura Group (Philip Morris International): Specialty formulation and drug delivery company with proprietary particle engineering technologies for inhaled and oral formulations — comparable in platform-based approach to addressing drug delivery challenges.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/nanocopoeia

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanocopoeia